SRL Diagnostics to test the genetic risks of heart diseases
SRL Diagnostics has developed a new way to identify the genetic risk associated with developing a heart disease. Suitable for people above 30 years of age, the once-in-a-lifetime test helps evaluate genetic markers associated with increased risk of coronary artery disease.
An official statement from the diagnostic chain implied that to develop the "Heart Ensure Panel" test, as it is clinically termed, has been arrived at after conducting several studies on the Indian population. Several tasks were undertaken to determine which genetic markers are relevant in the Indian context, so as to reach a medical conclusion.
This test may help curb the situation where millions of people in India are reported to die because of heart disease; knowing the genetic reasons behind heart disease may lead to improved preventive measures to deal with such problems.
"SRL has introduced 'Heart Ensure Panel' test which will evaluate genetic reasons behind the disease. This test should ideally be undertaken by individuals above the age of 30 years who may or may not have a family history of heart disease," said Leena Chatterjee, director of Fortis SRL Labs & SRL Strategic Initiatives.
"It should also be undertaken by those individuals who have dyslipidaemia (high levels of cholesterol) so as to reduce the progression of coronary artery disease by modifying the treatment and setting revised targets of controlling lipid levels," Chatterjee said.
Nearly 2.4 million Indians die due to heart disease every year, the statement said.
This panel of tests is important because it would encourage and enable an individual to be proactive about maintaining his/her own health, cut down on the lifestyle factors that can cause harm to heart health or consult a physician for therapeutic recommendations, thereby diminishing the risk as well as ensuring a holistic approach to countering heart diseases, Chatterjee said.
"Furthermore, this is a genetic test and has to be undertaken only once in life," she added.
SRL Diagnostics, the path lab chain of the Fortis Group has about 11 Reference Labs, 4 Centres of Excellence, 273* Network Laboratories and a footprint spanning over 6700 Collection Points across the country.
An official statement from the diagnostic chain implied that to develop the "Heart Ensure Panel" test, as it is clinically termed, has been arrived at after conducting several studies on the Indian population. Several tasks were undertaken to determine which genetic markers are relevant in the Indian context, so as to reach a medical conclusion.
This test may help curb the situation where millions of people in India are reported to die because of heart disease; knowing the genetic reasons behind heart disease may lead to improved preventive measures to deal with such problems.
"SRL has introduced 'Heart Ensure Panel' test which will evaluate genetic reasons behind the disease. This test should ideally be undertaken by individuals above the age of 30 years who may or may not have a family history of heart disease," said Leena Chatterjee, director of Fortis SRL Labs & SRL Strategic Initiatives.
"It should also be undertaken by those individuals who have dyslipidaemia (high levels of cholesterol) so as to reduce the progression of coronary artery disease by modifying the treatment and setting revised targets of controlling lipid levels," Chatterjee said.
Nearly 2.4 million Indians die due to heart disease every year, the statement said.
This panel of tests is important because it would encourage and enable an individual to be proactive about maintaining his/her own health, cut down on the lifestyle factors that can cause harm to heart health or consult a physician for therapeutic recommendations, thereby diminishing the risk as well as ensuring a holistic approach to countering heart diseases, Chatterjee said.
"Furthermore, this is a genetic test and has to be undertaken only once in life," she added.
SRL Diagnostics, the path lab chain of the Fortis Group has about 11 Reference Labs, 4 Centres of Excellence, 273* Network Laboratories and a footprint spanning over 6700 Collection Points across the country.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.